3B BlackBio Dx Limited (formerly Kilpest India Limited) announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing robust performance across both standalone and consolidated operations. The Board of Directors approved these results at their meeting held on February 6, 2026.

Consolidated Financial Performance

The company delivered impressive consolidated results for Q3FY26, with significant growth across key financial metrics. The diagnostic kits segment emerged as a major growth driver, contributing substantially to the overall performance.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, the consolidated performance showed consistent growth momentum across all major parameters.

Standalone Financial Results

The standalone operations also demonstrated solid performance, with revenue from operations reaching ₹2437.62 lakhs in Q3FY26 compared to ₹2343.00 lakhs in the corresponding previous quarter. Net profit for the standalone entity stood at ₹1446.02 lakhs versus ₹1344.84 lakhs in Q3FY25.

Segment-wise Performance

The company operates through two identified reportable business segments: Agrochemicals and Molecular Diagnostic Kits (Health Care Sector). The diagnostic kits segment showed remarkable performance with revenue of ₹4867.50 lakhs in Q3FY26 compared to ₹2328.30 lakhs in Q3FY25. The agrochemicals segment generated revenue of ₹167.23 lakhs during the quarter.

CORIS Acquisition Impact

The consolidated financials for Q3FY26 include CORIS sales of ₹2400.70 lakhs and profit of ₹700.10 lakhs. For the nine-month period, CORIS contributed sales of ₹2765.74 lakhs and profit of ₹658.20 lakhs, significantly enhancing the company's diagnostic capabilities and market presence.

Key Financial Highlights

Expense Management:

• Cost of materials consumed: ₹1367.34 lakhs (consolidated) vs ₹615.98 lakhs in Q3FY25
• Employee benefits expense: ₹821.31 lakhs vs ₹170.98 lakhs in previous year
• Other expenses included CE IVDR regulatory expenses and conference expenses

Balance Sheet Strength:

• Paid-up equity share capital: ₹856.84 lakhs
• Total segment assets: ₹41261.25 lakhs
• Capital employed: ₹35831.57 lakhs

Business Notes and Outlook

The company's agrochemical business remains seasonal in nature, with performance impacted by weather conditions and cropping patterns. The management noted that other expenses for the nine months included M&A expenses of ₹138.60 lakhs (₹84.06 lakhs in Q1 and ₹54.54 lakhs in Q2).

The company has evaluated the impact of new labour codes that became effective from November 21, 2025, determining that the impact on standalone financial results is not material. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by Baheti & Co., Chartered Accountants.

3b blackbio dx Limited has announced that its Board of Directors will convene on February 6, 2026, to review and approve the company's quarterly financial performance. The meeting represents a key milestone in the company's regulatory compliance and investor communication process.

Board Meeting Details

The board meeting has been scheduled with specific parameters to ensure proper governance and regulatory adherence:

Financial Results Scope

The board will review comprehensive financial statements covering multiple aspects of the company's performance. The meeting agenda includes consideration and approval of both unaudited standalone and consolidated financial results for the specified period. This dual approach provides stakeholders with a complete view of the company's financial position, including subsidiary performance and standalone operations.

Trading Window Restrictions

In compliance with SEBI regulations regarding insider trading, 3B BlackBio Dx Limited has implemented trading window restrictions to maintain market integrity:

Regulatory Compliance

The board meeting announcement fulfills the company's obligations under Regulation 29(1) and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally notified BSE Limited through its Department of Corporate Relations, ensuring proper disclosure to market participants and regulatory authorities.

The communication was signed by Nikhil Kuber Dubey, Whole Time Director, demonstrating appropriate corporate governance and executive oversight in the disclosure process.